Table 2 Secondary analyses: risk of lung cancer except for a specific subtype (leave-one-out approach) associated with cumulative use of flupentixol and any antipsychotics.
Total sample | Males | Females | ||||
|---|---|---|---|---|---|---|
Analysis one | Analysis two | Analysis one | Analysis two | Analysis one | Analysis two | |
Flupentixol | Any antipsychotics | Flupentixol | Any antipsychotics | Flupentixol | Any antipsychotics | |
Exclude malignant neoplasm of trachea (162.0) | ||||||
366–1825 days | 0.65 (0.47–0.91) | 0.42 (0.39–0.45) | 0.76 (0.50–1.13) | 0.41 (0.36–0.45) | 0.50 (0.28–0.91) | 0.43 (0.38–0.49) |
1826+ days | 0.74 (0.52–1.04) | 0.54 (0.49–0.60) | 0.67 (0.43–1.05) | 0.52 (0.46–0.60) | 0.87 (0.51–1.49) | 0.58 (0.50–0.67) |
Exclude malignant neoplasm of main bronchus (162.2) | ||||||
366–1825 days | 0.67 (0.48–0.94) | 0.42 (0.38–0.45) | 0.78 (0.52–1.17) | 0.41 (0.36–0.45) | 0.51 (0.28–0.92) | 0.43 (0.38–0.49) |
1826+ days | 0.75 (0.53–1.06) | 0.54 (0.49–0.60) | 0.70 (0.44–1.09) | 0.52 (0.46–0.60) | 0.86 (0.50–1.48) | 0.57 (0.49–0.67) |
Exclude malignant neoplasm of upper lobe, bronchus or lung (162.3) | ||||||
366–1825 days | 0.60 (0.39–0.91) | 0.41 (0.37–0.45) | 0.80 (0.49–1.31) | 0.40 (0.35–0.46) | 0.34 (0.15–0.77) | 0.42 (0.36–0.48) |
1826+ days | 0.74 (0.48–1.14) | 0.52 (0.46–0.59) | 0.54 (0.29–1.01) | 0.51 (0.43–0.60) | 1.15 (0.62–2.12) | 0.55 (0.46–0.66) |
Exclude malignant neoplasm of middle lobe, bronchus or lung (162.4) | ||||||
366–1825 days | 0.67 (0.48–0.94) | 0.41 (0.38–0.45) | 0.78 (0.52–1.17) | 0.40 (0.36–0.45) | 0.52 (0.29–0.95) | 0.43 (0.38–0.48) |
1826+ days | 0.72 (0.51–1.03) | 0.54 (0.49–0.60) | 0.65 (0.41–1.03) | 0.52 (0.45–0.59) | 0.86 (0.50–1.48) | 0.58 (0.50–0.68) |
Exclude malignant neoplasm of lower lobe, bronchus or lung (162.5) | ||||||
366–1825 days | 0.69 (0.48–1.00) | 0.43 (0.39–0.46) | 0.75 (0.48–1.17) | 0.40 (0.36–0.45) | 0.61 (0.33–1.15) | 0.46 (0.40–0.52) |
1826+ days | 0.67 (0.50–1.01) | 0.53 (0.48–0.59) | 0.69 (0.42–1.13) | 0.52 (0.45–0.60) | 0.64 (0.32–1.29) | 0.55 (0.46–0.65) |
Exclude malignant neoplasm of other parts of bronchus or lung (162.8) | ||||||
366–1825 days | 0.65 (0.47–0.91) | 0.42 (0.38–0.45) | 0.76 (0.51–1.14) | 0.41 (0.36–0.45) | 0.50 (0.28–0.90) | 0.43 (0.38–0.49) |
1826+ days | 0.74 (0.52–1.04) | 0.54 (0.49–0.60) | 0.68 (0.43–1.06) | 0.52 (0.46–0.59) | 0.86 (0.50–1.48) | 0.57 (0.49–0.66) |
Exclude malignant neoplasm of bronchus and lung, unspecified (162.9) | ||||||
366–1825 days | 0.60 (0.37–0.96) | 0.43 (0.38–0.48) | 0.63 (0.45-1.13) | 0.43 (0.37–0.50) | 0.54 (0.25-1.18) | 0.42 (0.35–0.51) |
1826+ days | 0.83 (0.54–1.28) | 0.59 (0.52–0.68) | 0.81 (0.48–1.39) | 0.56 (0.47–0.67) | 0.89 (0.44–1.80) | 0.65 (0.52–0.80) |
